Date of Approval: October 11, 2019

FREEDOM OF INFORMATION SUMMARY

ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-654

Tilmovet® and Monovet®

(tilmicosin) and (monensin Type A medicated article)

Type A medicated articles to be used in the manufacture of Type B and Type C medicated feeds

Cattle fed in confinement for slaughter

Original abbreviated new animal drug approval of a medicated feed combination for the indications listed in Section I.L

Sponsored by:

Huvepharma EOOD

Table of Contents

I. GENERAL INFORMATION

A. File Number

ANADA 200-654

B. Sponsor

Huvepharma EOOD,
5th Floor, 3A Nikolay Haytov Str.,
1113 Sofia, Bulgaria

Drug Labeler Code: 016592

US Agent Name and Address:
Kelly Beers, Ph.D.
Huvepharma, Inc.
525 West Park Drive
Peachtree City, GA 30269

C. Proprietary Name

Tilmovet® and Monovet®

D. Drug Product Established Name

tilmicosin and monensin Type A medicated article

E. Pharmacological Categories

Tilmovet®: Antimicrobial
Monovet®: Ionophore, anticoccidial

F. Dosage Form

Type A medicated articles for use in the manufacture of Type B and Type C medicated feeds.

G. Amount of Active Ingredients in Currently Marketed Products[1]

Tilmovet®: 90.7 g/lb (200 g/kg) of tilmicosin (as tilmicosin phosphate)
Monovet®: 90.7 g/lb of monensin

H. How Supplied

Tilmovet® (tilmicosin): 2.2 lb (1 kg), 11.0 lb (5 kg), 22.0 lb (10 kg) and 44.0 lb (20 kg) bags
Monovet® (monensin Type A medicated article): 55.12 lb (25 kg) bags

[1] The sponsors of these individual currently marketed Type A medicated articles may have approvals for other strengths of these products that are for use in the same species and class, for the same indications, and at the same dosages, but are not currently marketing those strengths of these Type A medicated articles. Such strengths, when legally marketed, are also approved for use in the manufacture of Type B and Type C medicated feeds that are the subject of this approval.

I. Dispensing Status

VFD

J. Route of Administration

Oral

K. Species/Class

Cattle fed in confinement for slaughter

L. Indications and Dosage Regimens

1. For improved feed efficiency and control of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida*, and *Histophilus somni* in groups of cattle fed in confinement for slaughter, where active BRD has been diagnosed in at least 10% of the animals in the group.

    a. 568 to 757 g/ton of Tilmovet® for control of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida*, and *Histophilus somni* in groups of cattle fed in confinement for slaughter, where active BRD has been diagnosed in at least 10% of the animals in the group.

    b. 5 to 40 g/ton of Monovet® for improved feed efficiency.

    This Type C medicated feed is to be fed continuously as the sole ration for a single, 14 day period at 568 grams to 757 grams tilmicosin per ton on a 100% dry matter basis (511.2 to 681.3 g per ton on a 90% dry matter basis) to provide 12.5 mg tilmicosin/kg of body weight/day and 5 grams to 40 grams monensin per ton on a 90% dry matter basis (5.6 to 44.4 grams per ton on a 100% dry matter basis) to provide 50 to 480 mg monensin/head/day. No additional improvement in feed efficiency has been shown from feeding monensin at levels greater than 30 grams per ton on a 90% dry matter basis (360 mg monensin per head per day).

2. For prevention and control of coccidiosis due to *Eimeria bovis* and *Eimeria zuernii* and control of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida*, and *Histophilus somni* in groups of cattle fed in confinement for slaughter, where active BRD has been diagnosed in at least 10% of the animals in the group.

    a. 568 to 757 g/ton of Tilmovet® for control of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida*, and *Histophilus somni* in groups of cattle fed in confinement for slaughter, where active BRD has been diagnosed in at least 10% of the animals in the group.

    b. 10 to 40 g/ton of Monovet® for prevention and control of coccidiosis due to *Eimeria bovis* and *Eimeria zuernii*.

This Type C medicated feed is to be fed continuously as the sole ration for a single, 14 day period at 568 grams to 757 grams tilmicosin per ton on a 100% dry matter basis (511.2 to 681.3 g per ton on a 90% dry matter basis) to provide 12.5 mg tilmicosin/kg of body weight/day and 10 grams to 40 grams monensin per ton on a 90% dry matter basis (11.1 to 44.4 g per ton on a 100% dry matter basis) to provide 0.14 to 0.42 mg monensin/lb bodyweight per day, depending on the severity of the coccidiosis challenge, up to 480 mg/head/day.

M. Reference Listed New Animal Drug Combination

Pulmotil™ (tilmicosin) and Rumensin™ (monensin Type A medicated article); NADA 141-343; Elanco US Inc.

N. Approved Original Generic Type A Medicated Article

Monovet®; monensin Type A medicated article; ANADA 200-639; Huvepharma EOOD

O. Individual Type A medicated articles approved for use in the manufacture of the Type B and Type C combination medicated feeds in this application

Tilmovet® (tilmicosin); ANADA 200-509; Huvepharma EOOD
Monovet® (monensin Type A medicated article); ANADA 200-639; Huvepharma EOOD

II. BIOEQUIVALENCE

Under the provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) of 1988, an abbreviated new animal drug application (ANADA) may be submitted for a generic version of an approved new animal drug (reference listed new animal drug). New target animal safety and effectiveness data and human food safety data (other than tissue residue data) are not required for approval of an ANADA.

According to CVM's fourth policy letter issued on November 2, 1989, with regard to the implementation of GADPTRA, after the approval of an ANADA for a generic Type A medicated article, the generic sponsor is entitled to approval for all the feed-mixed combinations for which the RLNAD is approved. Bioequivalence and tissue residue studies are not required for the approval of the generic feed use combinations (Type B or C medicated feeds). Tilmicosin is codified under 21 CFR 558.618, monensin is codified under 21 CFR 558.355. The combination of tilmicosin and monensin is codified under 21 CFR 558.618.

III. EFFECTIVENESS

CVM did not require effectiveness studies for this approval.

IV. TARGET ANIMAL SAFETY

CVM did not require target animal safety studies for this approval.

V. HUMAN FOOD SAFETY

The following are assigned to this product for cattle fed in confinement for slaughter:

A. Acceptable Daily Intake and Tolerances for Residues

The acceptable daily intake (ADI) for total residues of tilmicosin is 25 micrograms *per* kilogram of body weight *per* day. The tolerances established for the feed use RLNAD apply to the generic feed use combination new animal drug product. A tolerance of 1.2 parts *per* million (ppm) is established for residues of tilmicosin (the marker residue) in liver, and 0.1 ppm in muscle, under 21 CFR 556.735.

The ADI for total residues of monensin is 12.5 micrograms *per* kilogram of body weight *per* day. The tolerances established for the feed use RLNAD apply to the generic feed use combination new animal drug product. A tolerance of 0.10 ppm is established for residues of monensin (the marker residue) in liver, and 0.05 ppm in muscle, kidney and fat, under 21 CFR 556.420.

B. Withdrawal Period

Consistent with CVM's fourth policy letter issued on November 2, 1989, with regard to the implementation of GADPTRA, after the approval of an ANADA for a generic Type A medicated article, the generic sponsor is entitled to approval for all the feed-mixed combinations for which the RLNAD is approved. Tissue residue studies are not required for the approval of the generic feed use combinations (Type B or Type C medicated feeds).

To this end, the withdrawal period for the generic combination Type B and Type C medicated feeds are those previously assigned to the RLNAD feed use combination. When used together, Tilmovet® (tilmicosin) and Monovet® (monensin Type A medicated article) are approved with a 28-day withdrawal period.

C. Analytical Method for Residues

The validated analytical methods for analysis of residues of tilmicosin and monensin are on file at the Center for Veterinary Medicine, 7500 Standish Place, Rockville, MD 20855. To obtain a copy of the analytical method, please submit a Freedom of Information request to:
https://www.accessdata.fda.gov/scripts/foi/FOIRequest/requestinfo.cfm.

VI. USER SAFETY

CVM did not require user safety studies for this original approval.

VII. AGENCY CONCLUSIONS

This information submitted in support of this ANADA satisfies the requirements of section 512(n) of the FD&C Act and demonstrates that Tilmovet® and Monovet®, when used according to the label, are safe and effective.

Additionally, data demonstrate that residues in food products derived from cattle fed in confinement from slaughter administered Tilmovet® and Monovet® will not represent a public health concern when the combination medicated feed is used according to the label.